Skip to main content
SpringerLink
Log in

Hepatitis C Virus Infection in Children Coinfected with HIV

Epidemiology and Management

  • Review Article
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

Mothers with hepatitis C virus (HCV) and HIV coinfection are the major source of HCV/HIV coinfection in infancy and childhood. There is no known intervention capable of interrupting HCV spread from mother to child, while the majority of infant HIV infections occurring in the developed world can be prevented by antiretroviral prophylaxis in the mother and child, elective caesarean section, and formula-feeding.

In the era preceding treatment of HIV infection with highly active antiretroviral therapy, HCV coinfection was of little concern because the short-term survival of patients with HIV infection prevented the slowly developing consequences of chronic hepatitis C. As the life expectancy of patients with HIV infection increased with therapy, HCV has emerged as a significant pathogen.

Several lines of evidence in adult patients suggest that liver disease may be more severe in patients coinfected with HIV and that progression of HIV disease may be accelerated by HCV coinfection. Whether coinfected children may share these clinical patterns remains a matter of speculation. Chronic hepatitis C in otherwise healthy children is usually a mild disease; liver damage may be sustained and fibrosis may increase over the years, suggesting slow progression of the disease.

Interferon-α has been the only drug used in the past decade to treat hepatitis C in children and adolescents, with average response rates of 20%. Preliminary results of treatment with interferon-α and ribavirin suggest that the efficacy would be greater with combined therapy. These treatment protocols have not yet been applied to children coinfected with HIV, but the increasing number of long-term survivors will probably prompt further investigation in the near future. At present, treating HIV disease and monitoring HCV infection and hepatotoxicity induced by antiretroviral drugs seem to be the more reasonable approach to HCV/HIV coinfection in childhood.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V

Similar content being viewed by others

References

  1. Sherman KE, Freeman S, Harrison S, et al. Prevalence of antibody to hepatitis C virus in patients infected with the human immunodeficiency virus. J Infect Dis 1991; 163: 414–5

    Article  PubMed  CAS  Google Scholar 

  2. Quan CM, Krajden M, Grigoriew GA, et al. Hepatitis C virus infection in patients infected with the immunodeficiency virus. Clin Infect Dis 1993; 17: 117–9

    Article  PubMed  CAS  Google Scholar 

  3. Marcellin P, Colin JF, Martinot-Peignoux M, et al. Hepatitis C virus infection in anti-HIV positive and negative French homosexual men with chronic hepatitis: comparison of second- and third-generation anti-HCV testing. Liver 1993; 13: 319–22

    PubMed  CAS  Google Scholar 

  4. Quaranta JF, Delaney SR, Alleman S, et al. Prevalence of antibody to hepatitis C virus (HCV) in HIV-1 infected patients. J Med Virol 1994; 42: 29–32

    Article  PubMed  CAS  Google Scholar 

  5. Sulkowski MS, Brinkley-Laughton S, Thomas DL. HCV and HIV coinfection: prevalence, genotype distribution and severity of liver disease in an urban HIV clinic [abstract]. Hepatology 2000; 32(4): 204

    Google Scholar 

  6. Brau N, Shahidi A, Bini E, et al. Hepatitis C and coinfection with HIV-1 in the New York City metropolitan area: a random survey among US veterans [abstract]. Hepatology 2000; 32(4): 469

    Google Scholar 

  7. Thomas DL, Villano SA, Riester KA, et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers: women and infants transmission study. J Infect Dis 1998; 177: 1480–8

    Article  PubMed  CAS  Google Scholar 

  8. Thomas SL, Newell ML, Peckham CS, et al. A review of hepatitis C virus (HCV) vertical transmission: risk of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection. Int J Epidemiol 1998; 27: 108–17

    Article  PubMed  CAS  Google Scholar 

  9. Tovo PA, Palomba E, Ferraris G, et al. Increased risk of maternal-infant hepatitis C transmission for women coinfected with human immunodeficiency virus type-1. Clin Infect Dis 1997; 25: 1121–4

    Article  PubMed  CAS  Google Scholar 

  10. Zanetti AR, Tanzi E, Paccagnini S, et al. Mother-to-infant transmission of hepatitis C virus. Lancet 1995; 345: 289–91

    Article  PubMed  CAS  Google Scholar 

  11. Dietrich DT. Hepatitis C virus and human immunodeficiency virus: clinical issues in coinfection. Am J Med 1999; 107: 79–84S

    Article  Google Scholar 

  12. Soriano V, Garcia-Samaniego J, Rodriguez-Rosado R, et al. Impact of chronic viral liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 1999; 15: 1–4

    Article  PubMed  CAS  Google Scholar 

  13. Telfer P, Sabin C, Deveraux H, et al. The progression of HCV associated liver disease in a cohort of hemophilia patients. Br J Haematol 1994; 87: 555–61

    Article  PubMed  CAS  Google Scholar 

  14. Martin P, Di Bisceglie A, Kassianides C, et al. Rapidly progressive non-A, non-B hepatitis in patients with HIV infection. Gastroenterology 1989; 97: 1559–61

    PubMed  CAS  Google Scholar 

  15. Thomas D, Shih J, Alter H, et al. Effect of HIV on hepatitis C virus infection among injecting drug users. J Infect Dis 1996; 174: 690–5

    Article  PubMed  CAS  Google Scholar 

  16. Ohto H, Terazawa S, Sasaki N, et al. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med 1994; 330: 744–50

    Article  PubMed  CAS  Google Scholar 

  17. Resti M, Azzari C, Mannelli F, et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV 1. BMJ 1998; 317: 437–41

    Article  PubMed  CAS  Google Scholar 

  18. Giacchino R, Tasso L, Timitilli A, et al. Vertical transmission of hepatitis C virus infection: usefulness of viremia detection in HIV-seronegative hepatitis C virus-seropositive mothers. J Pediatr 1998; 132: 167–9

    Article  PubMed  CAS  Google Scholar 

  19. Hepatitis C virus infection. American Academy of Pediatrics, Committee on Infectious Diseases. Pediatrics 1998; 101(3 Pt 1): 481–5

    Article  Google Scholar 

  20. Noell J, Rohde P, Ochs L, et al. Incidence and prevalence of chlamydia, herpes, and viral hepatitis in a homeless adolescent population. Sex Transm Dis 2001; 28: 4–10

    Article  PubMed  CAS  Google Scholar 

  21. Cervante S, Bustamante P, Ramirez Mayans JA, et al. Prevalence of antibodies against hepatitis C virus (HCV) in a population of Mexican children. Acta Gastroenterol Latinoam 1996; 26: 301–3

    Google Scholar 

  22. Marlins RM, Porto SO, Vanderborg BO, et al. Short report: prevalence of hepatitis C viral antibody among Brazilian children, adolescents and street youths. Am J Trop Med Hyg 1995; 53: 654–5

    Google Scholar 

  23. Romano L, Azara A, Chiaramonte M, et al. Low prevalence of anti-HCV antibody among Italian children. Infection 1994; 22: 350–2

    Article  PubMed  CAS  Google Scholar 

  24. Gil Miguel A, Ruedas A, Santos Santos M, et al. Prevalence of hepatitis virus infection in school children in an urban and suburban area of Madrid. Aten Primaria 1996; 15: 521–2

    Google Scholar 

  25. Muller Z, Deak J, Horanyi M, et al. The detection of hepatitis C virus in South Hungary. J Clin Virol 2001; 20: 81–3

    Article  PubMed  CAS  Google Scholar 

  26. Huang JF, Lu SN, Chue PY, et al. Hepatitis C virus infection among teenagers in an endemic township in Taiwan: epidemiological and clinical follow-studies. Epidemiol Infect 2001; 127: 485–92

    Article  PubMed  CAS  Google Scholar 

  27. Lee WS, Ng KP. Seroprevalence of anti-HCV in an urban child population: a preliminary study from Kuala Lumpur. Singapore Med J 2001; 42: 100–1

    PubMed  CAS  Google Scholar 

  28. Kitmdu J, Msengi A, Matee M, et al. Post-transfusion hepatitis C seroprevalence in Tanzanian children. Ann Trop Paediatr 2001; 21: 483–8

    Google Scholar 

  29. Darwish MA, Faris R, Darwish N, et al. Hepatitis C and cirrhotic liver disease in the Nile delta of Egypt: a community-based study. Am J Trop Med Hyg 2001; 64: 147–53

    PubMed  CAS  Google Scholar 

  30. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331: 1173–80

    Article  PubMed  CAS  Google Scholar 

  31. American Academy of Pediatrics. Identification and care of HIV-exposed and HIV-infected infants, children, and adolescents in foster care. Pediatrics 2000; 106: 149–53

    Article  Google Scholar 

  32. Papaevangelou V, Pollak H, Rochford G, et al. Increased vertical transmission of hepatitis C virus (HCV) infection to human immunodeficiency virus (HIV) infected infants of HIV and HCV coinfected women. J Infect Dis 1998; 178: 1047–52

    Article  PubMed  CAS  Google Scholar 

  33. Barlow KM, Mok JY. Dizygotic twins discordant for HIV and hepatitis C virus. Arch Dis Child 1993; 68: 507

    Article  PubMed  CAS  Google Scholar 

  34. Hershow RC, Reister KA, Lew J, et al. Increased vertical transmission of human immunodeficiency virus from coinfected mothers: women and infants transmission study. J Infect Dis 1997; 176: 414–20

    Article  PubMed  CAS  Google Scholar 

  35. Boyer PJ, Dillon M, Navaie M, et al. Factors predictive of maternal-fetal transmission of HIV-1: preliminary analysis of zidovudine given during pregnancy and/or delivery. JAMA 1994; 271: 1925–30

    Article  PubMed  CAS  Google Scholar 

  36. Borkowsky W, Krasinsky K, Cao Y, et al. Correlation of perinatal transmission of human immunodeficiency virus type 1 with maternal viremia and lymphocyte phenotypes. J Pediatr 1994; 125: 345–51

    Article  PubMed  CAS  Google Scholar 

  37. Weiser B, Nachman S, Tropper P, et al. Quantitation of human immunodeficiency virus type 1 during pregnancy: relationship of viral titer to mother-to-child transmission and stability of viral load. Proc Natl Acad Sci USA 1994; 91: 8037–41

    Article  PubMed  CAS  Google Scholar 

  38. Nduati RW, John GC, Mbori-Ngacha A, et al. Breastmilk transmission of HIV-1: a randomized clinical trial of breastfeeding and formula feeding. JAMA 2000; 283: 1167–74

    Article  PubMed  CAS  Google Scholar 

  39. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996; 335: 1678–81

    Article  Google Scholar 

  40. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1. N Engl J Med 1999; 340: 977–87

    Article  Google Scholar 

  41. Eriksen N. Perinatal consequences of hepatitis C. Clin Obstet Gynecol 1999; 42: 121–33

    Article  PubMed  CAS  Google Scholar 

  42. Hillemans P, Dannecker C, Kimming R, et al. Obstetric risk and vertical transmission of hepatitis C virus infection in pregnancy. Acta Obstet Gynecol Scand 2000; 79: 543–7

    Article  Google Scholar 

  43. Spencer JD, Latt N, Beeby PJ, et al. Transmission of hepatitis C virus to infants of human immunodeficiency virus negative intravenous drug-using mothers: rate of infection and assessment of risk factors for transmission. J Viral Hepat 1997; 4: 395–409

    Article  PubMed  CAS  Google Scholar 

  44. American Academy of Pediatrics Committee on Infectious Diseases. Hepatitis C virus infection. Pediatrics 1998; 101: 481–4

    Article  Google Scholar 

  45. Lin HH, Kao JK, Hsu HY, et al. Absence of infection in breast-fed infants born to hepatitis C virus-infected mothers. J Pediatr 1995; 126: 589–91

    Article  PubMed  CAS  Google Scholar 

  46. Kumar RM, Shahul S. Role of breast feeding in transmission of hepatitis C virus to infants of HCV-infected mothers. J Hepatol 1998; 29: 191–7

    Article  PubMed  CAS  Google Scholar 

  47. Polywka S, Schroter M, Feucht H-H, et al. Low risk of vertical transmission of hepatitis C virus by breast milk. Clin Infect Dis 1999; 29: 1327–9

    Article  PubMed  CAS  Google Scholar 

  48. Simpson RM, Hubbard BS, Zhao TM, et al. Experimental perinatal transmission of human immunodeficiency virus type 1 by passage of infected cells. J Infect Dis 1997; 175: 1337–43

    Article  PubMed  CAS  Google Scholar 

  49. Azzari C, Resti M, Moriondo M, et al. Vertical transmission of HCV is related to maternal peripheral blood mononuclear cell infection. Blood 2000; 96: 2045–8

    PubMed  CAS  Google Scholar 

  50. Cooper ER, Nugent RP, Diaz C, et al. After AIDS clinical trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. Women and Infants Transmission Study Group. J Infect Dis 1996; 174: 1207–11

    Article  PubMed  CAS  Google Scholar 

  51. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354: 795–802

    PubMed  CAS  Google Scholar 

  52. Frenkel I, Cowles M, Shapiro D, et al. The protective effect of zidovudine on the vertical transmission of HIV-1 appears to be primarily due to oral maternal zidovudine (ZDV) during late gestation. J Infect Dis 1996; 175: 971–4

    Article  Google Scholar 

  53. Wade NA, Bikhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998; 339: 1409–14

    Article  PubMed  CAS  Google Scholar 

  54. Centers for Disease Control and Prevention. US Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR Morb Mortal Wkly Rep 1998; 47: 1–30

    Google Scholar 

  55. Delamare C, Burgard M, Mayaux MJ, et al. HIV-1 RNA detection in plasma for the diagnosis of infection in neonates. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15: 121–5

    Article  PubMed  CAS  Google Scholar 

  56. Steketee RW, Abrams EJ, Thea DM, et al. Early detection of perinatal human immunodeficiency virus (HIV) type 1 infection using HIV RNA amplification and detection. J Infect Dis 1997; 175: 707–11

    Article  PubMed  CAS  Google Scholar 

  57. Pawlotsky JM. Diagnostic tests for hepatitis C. J Hepatol 1999; 31Suppl. 1: 71–9

    Article  PubMed  Google Scholar 

  58. Martinot-Peignoux M, Boyer N, Le Breton V, et al. A new step toward standardization of serum hepatitis C virus-RNA quantification in patients with chronic hepatitis C. Hepatology 2000; 31: 726–9

    Article  PubMed  CAS  Google Scholar 

  59. Gibb DM, Goodall RL, Dunn DT, et al. Mother to child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet 2000; 356: 904–7

    Article  PubMed  CAS  Google Scholar 

  60. Collier J, Heathcote J. Hepatitis C viral infection in the immunosuppressed patients. Hepatology 1998; 27: 2–6

    Article  PubMed  CAS  Google Scholar 

  61. EASL International Consensus Conference on Hepatitis C: Paris, 26-28 February 1999. Consensus statement. European Association for the Study of the Liver. J Hepatol 1999; 30: 956–61

    Article  Google Scholar 

  62. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26: 1–5

    Article  PubMed  CAS  Google Scholar 

  63. Eyster MW, Diamondstone LS, Lien JM, et al. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. J Acquir Immune Defic Syndr 1993; 6: 602–10

    PubMed  CAS  Google Scholar 

  64. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C coinfected patients. Hepatology 1999; 30: 1054–8

    Article  PubMed  CAS  Google Scholar 

  65. Thursz MR, Hill AV, Trepo C, et al. Polymorphism in genes affecting TH1/TH2 balance influence the outcome of HBV and HCV infection [abstract]. Hepatology 1998; 28: 575A

    Google Scholar 

  66. Bortolotti F, Tagger A, Giacchino R, et al. Hepatitis G and C virus coinfection in children. J Pediatr 1997; 131: 503–6

    Google Scholar 

  67. Tovo PA, Pembrey LJ, Newell M-L. Persistence rate and progression of vertically acquired hepatitis C infection. J Infect Dis 2000; 181: 419–24

    Article  PubMed  CAS  Google Scholar 

  68. Bortolotti F, Jara P, Diaz C, et al. Post-transfusion and community-acquired hepatitis C in childhood. J Pediatr Gastroenterol Nutr 1994; 18: 279–83

    Article  PubMed  CAS  Google Scholar 

  69. Guido M, Rugge M, Jara P, et al. Chronic hepatitis C in children: the pathological and clinical spectrum. Gastroenterology 1998; 115: 1525–9

    Article  PubMed  CAS  Google Scholar 

  70. Badizadegan K, Jonas MM, Ott MI, et al. Histopathology of the liver in children with chronic hepatitis C viral infection. Hepatol 1998; 28: 1416–23

    Article  CAS  Google Scholar 

  71. Weintrub P, Veereman-Wauters G, Cowan MJ, et al. Hepatitis C virus infection in infants whose mothers took street drugs intravenously. J Pediatr 1991; 119: 869–74

    Article  PubMed  CAS  Google Scholar 

  72. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV cohort study. Lancet 2000; 356: 1800–5

    Article  PubMed  CAS  Google Scholar 

  73. Piroth L, Duong M, Quantin C, et al. Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients. AIDS 1998; 12: 381–8

    Article  PubMed  CAS  Google Scholar 

  74. Lesens O, Deschenes M, Steben M, et al. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus positive hemophilics and should be treated as an opportunistic infection. J Infect Dis 1999; 179: 1254–8

    Article  PubMed  CAS  Google Scholar 

  75. Sabin CA, Telfer P, Phillips AN, et al. The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men. J Infect Dis 1997; 175(1): 164–8

    Article  PubMed  CAS  Google Scholar 

  76. De Martino M, Tovo PA, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. JAMA 2000; 284: 190–7

    Article  PubMed  Google Scholar 

  77. De Martino M, Tovo PA, Galli L, et al. Features of children perinatally infected with HIV-1 surviving longer than 5 years. Lancet 1994; 343: 191–5

    Article  Google Scholar 

  78. Grubman S, Gross E, Lerner-Weiss N, et al. Older children and adolescents living with perinatally acquired human immunodeficiency virus infection. Pediatrics 1995; 95: 657–63

    PubMed  CAS  Google Scholar 

  79. Galli L, de Martino M, Tovo PA, et al. Onset of clinical signs in children with HIV-1 perinatal infection. AIDS 1995; 9: 455–61

    PubMed  CAS  Google Scholar 

  80. Soriano V, Rodriguez-Rosado R, Garcia Samaniego J. Management of chronic hepatitis C in HIV-infected patients. AIDS 1999; 13: 539–46

    Article  PubMed  CAS  Google Scholar 

  81. Rodriguez-Rosado R, Garcia Samaniego J, Soriano V. Hepatotoxicity after introduction of highly active antiretroviral therapy [letter]. AIDS 1998; 12: 1256

    Article  PubMed  CAS  Google Scholar 

  82. Sulkowski M. Hepatitis C virus infection in HIV-infected patients. Curr Infect Dis Rep 2001; 3: 469–76

    Article  PubMed  Google Scholar 

  83. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989; 321: 1501–6

    Article  PubMed  CAS  Google Scholar 

  84. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C: a random controlled trial. N Engl J Med 1989; 321: 1506–10

    Article  PubMed  Google Scholar 

  85. Nischiguchi S, Kuroki T, Nakatani S, et al. Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051–5

    Article  Google Scholar 

  86. Soriano V, Garcia-Samaniego J, Bravo R, et al. Interferon alfa for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Clin Infect Dis 1996; 23: 285–91

    Article  Google Scholar 

  87. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse in chronic hapatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1543–9

    Article  Google Scholar 

  88. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485–92

    Article  PubMed  CAS  Google Scholar 

  89. Dietrich DT. An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. J Infect Dis 2002; 185Suppl. 2: S128–137

    Article  Google Scholar 

  90. Landau A, Batisse D, Van Huyen JP, et al. Efficacy and safety of combination therapy with interferon alpha 2b and ribavirin for chronic hepatitis C in HIV infected patients. AIDS 2000; 5: 839–44

    Article  Google Scholar 

  91. Nasti G, di Gennaro G, Rizzardini G, et al. Chronic hepatitis C in HIV-coinfected patients: feasibility and efficacy of interferon alfa2b and ribavirin combination therapy. J Acquir Immune Defic Syndr 2001; 26: 299–300

    Article  PubMed  CAS  Google Scholar 

  92. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa 2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666–72

    Article  PubMed  CAS  Google Scholar 

  93. Centers for Disease Control and Prevention. Guidelines for the use of antiretroviral agents in pediatric HIV infection. MMWR Morb Mortal Wkly Rep 1998; 47: 1–43

    Google Scholar 

  94. Italian register for HIV infection in children. Italian guidelines for antiretroviral therapy in children with human immunodeficiency virus type 1 infection. Acta Paediatr 1999; 88: 228–32

    Article  Google Scholar 

  95. Guidelines for the use of antiretroviral agents in pediatric HIV infection [online]. Available from URL: http:/www.hivatis.org/guidelines/pediatric/decl2_01/peddec.pdf [Accessed 2002 Jun 3]

  96. Mueller BU, Sleasman J, Nelson RP, et al. A phase I/II study of the protease inhibitor indinavir in children with HIV infection. Pediatrics 1998; 102: 101–9

    Article  PubMed  CAS  Google Scholar 

  97. Luzuriaga K, Bryson Y, Krogstad P, et al. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med 1997; 336: 1343–9

    Article  PubMed  CAS  Google Scholar 

  98. Kline MW, Blanchard S, Fletcher CV, et al. A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. Pediatrics 1999; 103: 1–5

    Article  Google Scholar 

  99. den Brinker M, Wit FW, Wertheim-van Dillen PME, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14: 2895–902

    Article  Google Scholar 

  100. Watson DC, Farley JJ. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 1999; 18: 682–9

    Article  PubMed  CAS  Google Scholar 

  101. Jacobson KR, Murray K, Zellos A, et al. An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2002; 34: 52–8

    Article  PubMed  CAS  Google Scholar 

  102. Clemente MG, Congia M, Lai MF, et al. Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C. J Pediatr 1994; 125(1): 123–8

    Article  PubMed  CAS  Google Scholar 

  103. Bortolotti F, Giacchino R, Vajro P, et al. Recombinant interferon alpha therapy in children with chronic hepatitis C. Hepatol 1995; 22: 1623–7

    Article  CAS  Google Scholar 

  104. Iorio R, Pensati P, Porzio S, et al. Lymphoblastoid interferon alfa treatment in chronic hepatitis C. Arch Dis Child 1996; 74: 152–6

    Article  PubMed  CAS  Google Scholar 

  105. Jonas M, Ott MJ, Nelson SP, et al. Interferon-alpha treatment of chronic hepatitis C virus infection in children. Pediatr Infect Dis J 1998; 17: 241–6

    Article  PubMed  CAS  Google Scholar 

  106. Pensati P, Iorio R, Botta S, et al. Low virological response to interferon in children with chronic hepatitis C. J Hepatol 1999; 3: 604–11

    Article  Google Scholar 

  107. Bunn S, Kelly D, Murray KF, et al. Safety, efficacy and pharmacokinetics of interferon alfa-2b and ribavirin in children with chronic hepatitis C [abstract]. Hepatology 2000; 32Pt 2: 350A

    Google Scholar 

  108. Woynarowski M, Socha J, Kuidowicz J, et al. Interferon + ribavirin vs interferon alone in treatment of children with chronic HCV infection [abstract]. J Hepatol 2001; 34Suppl. 1: 139S

    Google Scholar 

  109. Lackner H, Moser A, Deutsch J, et al. Interferon-alfa and ribavirin in treating children and young adults with chronic hepatitis C after malignancy. Pediatrics 2000; 106: 1–4

    Article  Google Scholar 

  110. Christensson B, Wiebe T, Akesson A, et al. Interferon-alpha and ribavirin treatment of hepatitis C in children with malignancy in remission. Clin Infect Dis 2000; 30: 585–6

    Article  PubMed  CAS  Google Scholar 

  111. Buti M, Sanchez-Avila F, Lurie Y, et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alpha-2b plus ribavirin. Hepatology 2002; 35: 930–6

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work has been partially supported by the Meyer Pediatric Hospital (research funds). The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

Author information

Authors and Affiliations

  1. Department of Pediatrics, University of Florence, Via Luca Giordano 13, Florence, I-50132, Italy

    Massimo Resti & Chiara Azzari

  2. Department of Clinical and Experimental Medicine, University of Padua, Padua, Italy

    Flavia Bortolotti

Authors
  1. Massimo Resti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chiara Azzari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Flavia Bortolotti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Massimo Resti.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Resti, M., Azzari, C. & Bortolotti, F. Hepatitis C Virus Infection in Children Coinfected with HIV. Pediatr-Drugs 4, 571–580 (2002). https://doi.org/10.2165/00128072-200204090-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128072-200204090-00003

Keywords

Search

Navigation